Trials / Completed
CompletedNCT04869488
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
An Open, Multi-center, Phase Ⅱ Clinical Study of Fluzoparib Combined With Apatinib or Fluzoparib in the Treatment of Metastatic Castration-resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Main research purpose: To evaluate the effectiveness of Fluzoparib combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | Fluzoparib Orally twice daily（Cohort 1、Cohort 4） |
| DRUG | Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets | Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1） |
| DRUG | Fluzoparib Combined With Apatinib | Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4） |
Timeline
- Start date
- 2021-07-19
- Primary completion
- 2023-02-14
- Completion
- 2023-02-14
- First posted
- 2021-05-03
- Last updated
- 2025-01-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04869488. Inclusion in this directory is not an endorsement.